Synthaverse S.A. (WSE:SVE)

Market Cap	217.08M -39.1%
Revenue (ttm)	42.19M -40.8%
Net Income	-23.00M
EPS	-0.31
Shares Out	75.77M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,159
Open	2.860
Previous Close	2.860
Day's Range	2.830 - 2.895
52-Week Range	2.600 - 5.400
Beta	0.08
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 30, 2026

About Synthaverse

Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents in Poland, rest of the European Union, and internationally. It operates through BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladder tumors; GAMMA anty-D 50 and GAMMA anty-D 150, which are human anti-rh0(d) immunoglobulin products used in the prevention of maternal-fetal conflict in terms of the D antigen...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1944
• Employees: 214
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: SVE

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 3, 2026

Data Sources Report a data error